A potential first-in-class, disease-modifying therapy for Mild Cognitive Impairment (MCI) and early Alzheimer’s Disease (AD), mechanism to restore brain positions as a differentiated therapy in a landscape dominated by amyloid-targeting drugs, addressing the fundamental neurodegenerative processes of AD. The asset is currently in nonclinical development, with plans to the final IND-enabling studies, GMP manufacturing, and readiness for first-in-human trials.